RS56676B1 - Poboljšana tnf veziva - Google Patents

Poboljšana tnf veziva

Info

Publication number
RS56676B1
RS56676B1 RS20171299A RSP20171299A RS56676B1 RS 56676 B1 RS56676 B1 RS 56676B1 RS 20171299 A RS20171299 A RS 20171299A RS P20171299 A RSP20171299 A RS P20171299A RS 56676 B1 RS56676 B1 RS 56676B1
Authority
RS
Serbia
Prior art keywords
tnf binders
improved tnf
improved
binders
tnf
Prior art date
Application number
RS20171299A
Other languages
English (en)
Inventor
Marie-Ange Buyse
Joachim Boucneau
Peter Casteels
Heeke Gino Van
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of RS56676B1 publication Critical patent/RS56676B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Organic Insulating Materials (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
RS20171299A 2015-11-12 2016-11-14 Poboljšana tnf veziva RS56676B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562254375P 2015-11-12 2015-11-12
PCT/EP2016/077595 WO2017081320A1 (en) 2015-11-12 2016-11-14 Improved tnf binders
EP16798122.4A EP3191511B1 (en) 2015-11-12 2016-11-14 Improved tnf binders

Publications (1)

Publication Number Publication Date
RS56676B1 true RS56676B1 (sr) 2018-03-30

Family

ID=57348648

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20171299A RS56676B1 (sr) 2015-11-12 2016-11-14 Poboljšana tnf veziva

Country Status (36)

Country Link
US (2) US10544211B2 (sr)
EP (2) EP3266798A3 (sr)
JP (2) JP6962915B2 (sr)
KR (2) KR20240029115A (sr)
CN (1) CN108473563B (sr)
AU (2) AU2016352943B2 (sr)
BR (1) BR112018009714A8 (sr)
CA (2) CA3234178A1 (sr)
CL (1) CL2018001291A1 (sr)
CO (1) CO2018005915A2 (sr)
CR (1) CR20180311A (sr)
CY (1) CY1120303T1 (sr)
DK (1) DK3191511T3 (sr)
DO (1) DOP2018000122A (sr)
EC (1) ECSP18042569A (sr)
ES (1) ES2662418T3 (sr)
GT (1) GT201800095A (sr)
HK (1) HK1248716A1 (sr)
HR (1) HRP20171949T1 (sr)
HU (1) HUE035805T2 (sr)
IL (2) IL310373A (sr)
LT (1) LT3191511T (sr)
MA (1) MA41653A (sr)
MD (1) MD3191511T2 (sr)
ME (1) ME02954B (sr)
MX (1) MX2018005992A (sr)
NO (1) NO2768984T3 (sr)
PE (1) PE20181317A1 (sr)
PH (1) PH12018501025A1 (sr)
PL (1) PL3191511T3 (sr)
PT (1) PT3191511T (sr)
RS (1) RS56676B1 (sr)
SG (1) SG11201803975SA (sr)
SI (1) SI3191511T1 (sr)
TN (1) TN2018000159A1 (sr)
WO (1) WO2017081320A1 (sr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2723769B2 (en) 2011-06-23 2022-06-15 Ablynx NV Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
SI3248986T1 (sl) 2014-05-16 2022-04-29 Ablynx Nv Variabilne domene imunoglobulina
NO2768984T3 (sr) * 2015-11-12 2018-06-09
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
EP4069293A1 (en) 2019-12-06 2022-10-12 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l
CN114981300A (zh) 2019-12-06 2022-08-30 艾伯霖克斯公司 包含靶向TNFα和IL-23的免疫球蛋白单个可变结构域的多肽
CN112300289B (zh) * 2019-12-30 2022-06-10 中国药科大学 RGD4C融合抗TNFα纳米抗体蛋白、制备方法及其应用
JP2023553694A (ja) * 2020-12-18 2023-12-25 アブリンクス エン.ヴェー. IL-6およびTNF-αを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
WO2024097571A1 (en) * 2022-11-04 2024-05-10 St. Jude Children's Research Hospital, Inc. Nlrp12 and nlrc5 modulators and methods for using the same to modulate diseases
WO2024133935A1 (en) 2022-12-23 2024-06-27 Ablynx Nv Protein-based conjugation carriers
US20240368250A1 (en) 2023-02-17 2024-11-07 Ablynx N.V. Polypeptides binding to the neonatal fc receptor

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334258D1 (de) 1992-08-21 2009-02-26 Univ Bruxelles Immunoglobuline ohne Leichtkette
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
AU2152299A (en) 1997-10-27 1999-05-24 Unilever Plc Multivalent antigen-binding proteins
KR20010034512A (ko) 1998-02-19 2001-04-25 베렌슨, 론 림프구 활성화 조절을 위한 조성물 및 그 방법
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
NZ540195A (en) 2002-11-08 2009-01-31 Ablynx Nv Stabilized single domain antibodies
CN101412759A (zh) 2003-01-10 2009-04-22 埃博灵克斯股份有限公司 治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用
DK1639011T3 (da) 2003-06-30 2009-02-16 Domantis Ltd Pegylerede enkelt-domæne antistoffer (dAb)
DE60334645D1 (de) 2003-11-07 2010-12-02 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
CA2583017A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
KR20070086896A (ko) 2004-12-02 2007-08-27 도만티스 리미티드 항­il­1r1 단일 도메인 항체 및 치료적 용도
SG184709A1 (en) * 2005-05-18 2012-10-30 Ablynx Nv Improved nanobodies™ against tumor necrosis factor-alpha
KR101414438B1 (ko) 2005-05-20 2014-07-10 아블린쓰 엔.브이. 폰 빌레브란트 인자에 대한 단일 도메인 vhh 항체
DE102005023617A1 (de) * 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
JP5049973B2 (ja) 2005-08-30 2012-10-17 アクトジェニックス・エヌブイ 慢性全腸炎の治療のための、抗−TNFα産生乳酸菌
TW200730539A (en) 2005-12-01 2007-08-16 Domantis Ltd Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
EA200801166A1 (ru) 2005-12-01 2008-12-30 Домантис Лимитед Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
CA2640066A1 (en) 2006-01-24 2007-08-02 Roland Beckmann Fusion proteins that contain natural junctions
CA2666599A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
CN101611056A (zh) 2006-12-05 2009-12-23 埃博灵克斯股份有限公司 能够结合于血清蛋白的肽
KR101264473B1 (ko) 2007-05-24 2013-05-29 아블린쓰 엔.브이. Rank-l에 대한 아미노산 서열, 및 이를 포함하는 골 질환 및 장애 치료용 폴리펩티드
WO2009068625A2 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
EP2285833B1 (en) 2008-05-16 2014-12-17 Ablynx N.V. AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
JP2012517818A (ja) * 2009-02-19 2012-08-09 グラクソ グループ リミテッド 改善された抗tnfr1ポリペプチド、抗体可変ドメインおよびアンタゴニスト
AU2010233658B2 (en) 2009-04-10 2013-11-28 Ablynx Nv Improved amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of IL-6R related diseases and disorders
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
JP2012532620A (ja) 2009-07-16 2012-12-20 グラクソ グループ リミテッド 改良型抗血清アルブミン結合単一可変ドメイン
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
CN103917560B (zh) 2011-03-28 2017-05-24 埃博灵克斯股份有限公司 双特异性抗‑cxcr7免疫球蛋白单可变结构域
EP2723771B1 (en) 2011-06-23 2019-09-11 Ablynx NV Serum albumin binding proteins
EP2723769B2 (en) * 2011-06-23 2022-06-15 Ablynx NV Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2987806A3 (en) 2011-08-17 2016-07-13 Glaxo Group Limited Modified single variable domain antibodies with reduced binding to anti-drug-antibodies
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
SI3248986T1 (sl) 2014-05-16 2022-04-29 Ablynx Nv Variabilne domene imunoglobulina
NO2768984T3 (sr) 2015-11-12 2018-06-09
AU2017216864B2 (en) * 2016-02-12 2023-06-22 Ablynx Nv Method for the production of immunoglobulin single variable domains

Also Published As

Publication number Publication date
EP3191511A1 (en) 2017-07-19
KR20240029115A (ko) 2024-03-05
PH12018501025A1 (en) 2019-01-28
CA3234178A1 (en) 2017-05-18
US20170190769A1 (en) 2017-07-06
IL259269A (en) 2018-07-31
ES2662418T3 (es) 2018-04-06
GT201800095A (es) 2019-08-15
PT3191511T (pt) 2017-11-30
CL2018001291A1 (es) 2018-09-14
HRP20171949T1 (hr) 2018-01-26
IL259269B2 (en) 2024-07-01
SG11201803975SA (en) 2018-06-28
DK3191511T3 (en) 2018-01-08
CO2018005915A2 (es) 2018-06-20
AU2016352943B2 (en) 2022-10-20
AU2016352943A1 (en) 2018-06-07
JP2022020666A (ja) 2022-02-01
JP6962915B2 (ja) 2021-11-10
MA41653A (fr) 2018-01-09
US9745372B2 (en) 2017-08-29
HK1248716A1 (zh) 2018-10-19
BR112018009714A2 (pt) 2018-11-21
IL310373A (en) 2024-03-01
EP3266798A3 (en) 2018-03-28
CN108473563B (zh) 2022-06-14
TN2018000159A1 (en) 2019-10-04
US20170267752A1 (en) 2017-09-21
MD3191511T2 (ro) 2018-03-31
EP3191511B1 (en) 2017-09-20
WO2017081320A1 (en) 2017-05-18
SI3191511T1 (en) 2018-01-31
EP3266798A2 (en) 2018-01-10
LT3191511T (lt) 2018-01-10
DOP2018000122A (es) 2018-09-30
RU2018120524A3 (sr) 2020-09-24
CN108473563A (zh) 2018-08-31
ECSP18042569A (es) 2018-07-31
HUE035805T2 (en) 2018-05-28
PE20181317A1 (es) 2018-08-14
CY1120303T1 (el) 2019-07-10
RU2018120524A (ru) 2019-12-13
IL259269B1 (en) 2024-03-01
US10544211B2 (en) 2020-01-28
CA3005085A1 (en) 2017-05-18
AU2023200113A1 (en) 2023-02-16
ME02954B (me) 2018-07-20
BR112018009714A8 (pt) 2019-02-26
JP7357038B2 (ja) 2023-10-05
CR20180311A (es) 2018-10-18
KR102641194B1 (ko) 2024-02-26
NO2768984T3 (sr) 2018-06-09
KR20180083382A (ko) 2018-07-20
JP2019506839A (ja) 2019-03-14
PL3191511T3 (pl) 2018-03-30
MX2018005992A (es) 2019-01-31

Similar Documents

Publication Publication Date Title
HK1254952A1 (zh) Ctla4結合劑
IL259269A (en) Enhanced TNF-binding agents
HK1245235A1 (zh) 固體形式
PL3146010T3 (pl) Środki wiążące
PL3237350T3 (pl) Ulepszony środek wiążący
GB201518594D0 (en) Solid formation
GB201412335D0 (en) Binder
GB201610063D0 (en) Binders
SI3341334T1 (sl) Polprevodniško vezivo
PL3386753T3 (pl) Rakiel
GB2537722B (en) Booklet
PL3256331T3 (pl) Dokument
GB201413311D0 (en) Book
SI3393992T1 (sl) Vezivo, ki vsebuje oksoogljik
GB201520104D0 (en) Scraper
ZA201801356B (en) Firelighter
SI3341335T1 (sl) Polprevodniško vezivo
GB201418800D0 (en) TIO2-Latex composite binder
HRP20181700T1 (hr) Fascikl
ZA201707980B (en) Binding folder
GB201518350D0 (en) Binding rings
FI12481U1 (fi) Kiinteä fraktio
GB201503832D0 (en) Inamo big book V3
GB201413567D0 (en) Binding surfaces
GB201419717D0 (en) Binder additive